Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CHKA | P35790 | 1/20 | 0.38 |
| ▸ | KDM5C | P41229 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL62990 | 1.00 | HSD17B10 (0.52) | HSD17B10CHRM5CHRM3SIGMAR1CA2 | |
| Hydrochloric Acid SCHEMBL31505485 | 0.98 | CHRM5 (0.50) | HSD17B10CHRM5CHRM3SIGMAR1CA2 | |
| Water SCHEMBL4953290 | 0.98 | CHRM5 (0.50) | HSD17B10CHRM5CHRM3SIGMAR1CA2 | |
| SCHEMBL29299554 | 0.98 | CHRM5 (0.50) | HSD17B10CHRM5CHRM3SIGMAR1CA2 | |
| SCHEMBL472190 | 0.98 | CHRM5 (0.50) | HSD17B10CHRM5CHRM3SIGMAR1CA2 | |
| SCHEMBL472213 | 0.98 | CHRM5 (0.50) | HSD17B10CHRM5CHRM3SIGMAR1CA2 | |
| Hydrochloric Acid SCHEMBL4441607 | 0.98 | CHRM5 (0.50) | HSD17B10CHRM5CHRM3SIGMAR1CA2 | |
| SCHEMBL306395 | 0.98 | CHRM5 (0.50) | HSD17B10CHRM5CHRM3SIGMAR1CA2 | |
| Hydrochloric Acid SCHEMBL1373260 | 0.98 | CHRM5 (0.50) | HSD17B10CHRM5CHRM3SIGMAR1CA2 | |
| SCHEMBL934786 | 0.98 | CHRM5 (0.50) | HSD17B10CHRM5CHRM3SIGMAR1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 314 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137819-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260097139-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GnRHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY INC (US) | 2026-04-09 | — | — | US | claimed |
| EP-4721765-A1 | BI-FUNCTIONALIZED ANTIBODY CONJUGATES AGAINST THE ENDOTHELIN RECEPTOR B | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2026-04-08 | — | — | EP | claimed |
| US-12521455-B2 | Kisspeptin receptor (KISS1R) targeted therapeutics and uses thereof | RADIONETICS ONCOLOGY, INC. (US) | 2026-01-13 | — | — | US | claimed |
| EP-4634174-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GNRHR) TARGETED THERAPEUTICS AND USES THEREOF | Radionetics Oncology, Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| WO-2025217074-A1 | KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2025-10-16 | — | — | WO | claimed |
| US-20250312499-A1 | KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2025-10-09 | — | — | US | claimed |
| EP-4622966-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | Radionetics Oncology, Inc. (US) | 2025-10-01 | — | — | EP | claimed |
| EP-4598928-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | Radionetics Oncology, Inc. (US) | 2025-08-13 | — | — | EP | claimed |
| US-20250213735-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2025-07-03 | — | — | US | claimed |
| WO-2012079582-A1 | ENTRAPMENT OF RADIONUCLIDES IN NANOPARTICLE COMPOSITIONS | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2012-06-21 | — | — | WO | claimed |
| EP-2453927-A1 | LOADING TECHNIQUE FOR PREPARING RADIONUCLIDE AND IONOPHORE CONTAINING LIPOSOMES IN WHICH THE IONOPHORE IS 2-HYDROXYQUIONOLINE (CARBOSTYRIL) OR STRUCTURALLY RELATED 2-HYDROXYQUINOLINES | Technical University of Denmark (DK) | 2012-05-23 | — | — | EP | claimed |
| EP-0998476-B1 | 1,4,7,10-TETRAAZABICYCLO 8.2.2]TETRADECAN-2-ONE, A PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF FOR THE PREPARATION OF TETRAAZAMACROCYCLES | BRACCO SPA (IT) | 2004-05-06 | — | — | EP | claimed |
| EP-0998466-B1 | A PROCESS FOR THE PREPARATION OF TETRAAZAMACROCYCLES | BRACCO IMAGING SPA (IT) | 2002-10-16 | — | — | EP | claimed |
| US-6162912-A | Process of preparing tetraacetic acid derivatives | DIBRA S.P.A. (IT) | 2000-12-19 | — | — | US | claimed |
| US-5922862-A | Process for the preparation of tetraazamacrocycles | DIBRA S.P.A. (IT) | 1999-07-13 | — | — | US | claimed |
| US-5428155-A | PH controlled sulfomethylation of 1,4,7,10-tetraazacyclododecane; displacement with sodium cyanide; hydrolysis to symmetrical acetic acid side groups | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1995-06-27 | — | — | US | claimed |
| EP-0618910-A1 | SYNTHESIS OF POLYAZAMACROCYCLES WITH MORE THAN ONE TYPE OF SIDE-CHAIN CHELATING GROUPS | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1994-10-12 | — | — | EP | claimed |
| US-5316757-A | MRI contrast agent | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1994-05-31 | — | — | US | claimed |
| WO-1993012097-A1 | SYNTHESIS OF POLYAZAMACROCYCLES WITH MORE THAN ONE TYPE OF SIDE-CHAIN CHELATING GROUPS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1993-06-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097139-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GnRHR) TARGETED THERAPEUTICS AND USES THEREOF | GNRHR, GHRHR, FSHR | HSD17B10 1239/4885CHRM5 3447/4885CHRM3 3470/4885 |
| US-20250213735-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | HSD17B10 3848/4885CHRM5 2123/4885CHRM3 1728/4885 |
| US-20250312499-A1 | KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF | KISS1R, GNRHR, PROKR1 | HSD17B10 3643/4885CHRM5 4097/4885CHRM3 3211/4885 |
| US-20260137819-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | FSHR, GNRHR, LHCGR | HSD17B10 568/4885CHRM5 2940/4885CHRM3 2831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.